Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.
Summary
Bill S00987 aims to amend the public health law and the insurance law to enhance access to abuse-deterrent opioid analgesics. It prohibits insurance carriers from requiring prior authorization for opioid analgesics without abuse-deterrent properties before allowing access to those with such properties. Additionally, it mandates that at least one abuse-deterrent opioid analgesic drug product be included in insurance formularies for each active ingredient, ensuring that cost-sharing for these products does not exceed that of non-abuse-deterrent counterparts.
Impact
The bill will significantly impact state laws regarding the prescription and insurance coverage of opioid medications. By ensuring that abuse-deterrent formulations are readily accessible and covered by insurance, the legislation aims to reduce opioid abuse and diversion. This could lead to a shift in prescribing practices, as healthcare providers may be more inclined to prescribe abuse-deterrent formulations knowing that they will be covered by insurance without additional costs to patients.
Sentiment
The sentiment surrounding Bill S00987 appears to be generally supportive, as it addresses the critical issue of opioid abuse and seeks to provide safer alternatives for pain management. However, there may be concerns regarding the implications for insurance costs and the potential burden on healthcare providers in adapting to new prescribing guidelines.
Contention
Notable points of contention may arise from insurance companies and healthcare providers regarding the financial implications of mandating coverage for abuse-deterrent opioids. Some stakeholders may argue that this could lead to increased insurance premiums or limit the availability of other treatment options. Additionally, there may be debates on the effectiveness of abuse-deterrent technologies in truly reducing opioid abuse.